Basal cell carcinoma
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Likokoana-hloko tse amang letlalo la nko ho motho ea tsofetseng hangata li fumanoa e le Basal cell carcinoma. Nko ke sebaka se tloaelehileng sa ketsahalo ea mofuta ona oa kankere ea letlalo.
Basal cell carcinoma e ka hlaha ka meedi e sa tlwaelehang le diso.
Basal cell carcinoma e ka 'na ea etsoa ka phoso bakeng sa wart.
References
Basal cell carcinoma (BCC) ke mofuta o atileng haholo oa mofetše oa letlalo. Khanya ea letsatsi ke eona sesosa se ka sehloohong. Hoo e ka bang linyeoe tsohle tsa BCC li bonts'a pontšo e feteletseng ea Hedgehog tlhahlobong ea limolek'hule. Liphekolo tse fapaneng lia fumaneha 'me li khethoa ho ipapisitsoe le kotsi ea ho khutla hape, bohlokoa ba ho baballa lisele, khetho ea mokuli le boholo ba lefu lena.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas ke mofuta o atileng haholo oa mofetše oa letlalo ho batho ba baholo ba letlalo le lesoeu ba lilemo li 50 ho ea holimo. Palo ea tsona e ntse e eketseha lefatšeng ka bophara, haholo-holo ka lebaka la ho pepesehela mahlaseli a letsatsi. Maemo a mang a liphatsa tsa lefutso a ka etsa hore batho ba sekamele ho ba le mofetše ona ba sa le banyenyane. Basal cell carcinomas e fapana ka ho teba, ho tloha ho maqeba a ka holimo kapa a maqhutsu a ka phekolehang habonolo ho isa ho a atileng haholo a hlokang puisano lihlopheng tse khethehileng tsa bongaka. Polelo e itšetlehile ka monyetla oa hore kankere e khutle kapa bokhoni ba eona ba ho senya lisele tse haufi. Ho buuoa ke mokhoa o tloaelehileng oa phekolo maemong a mangata, ho netefatsa ho tlosoa ka nepo le menyetla e fokolang ea ho pheta-pheta. Mekhoa e fokolang ea ts'oaetso e ka phekola maqeba a ka holimo ka katleho.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Kalafo ea mantlha ea BCC ke ho buuoa. Bakeng sa BCC e kotsing e kholo kapa e pheta-phetoang, haholo-holo libakeng tse mahlonoko, ho buelloa ho buuoa ka micrographically. Bakuli ba nang le BCC e kaholimo ho kotsi e tlase ba ka nahana ka kalafo ea lihlooho kapa mekhoa e kotsi. Phekolo ea Photodynamic e sebetsa hantle bakeng sa li-BCC tsa nodular tse kotsi le tse kotsi. Bakeng sa BCC e tsoetseng pele ea lehae kapa metastatic, Hedgehog inhibitors (vismodegib, sonidegib) ea khothaletsoa. Haeba ho na le tsoelo-pele ea mafu kapa ho se mamelle ho Hedgehog inhibitors, immunotherapy e nang le anti-PD1 antibody (cemiplimab) e ka nkoa. Radiotherapy ke khetho e ntle bakeng sa bakuli ba sa khoneng ho buuoa, haholo bakuli ba baholo. Electrochemotherapy e ka nahanoa haeba opereishene kapa radiotherapy e se khetho.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Lintho tse kotsi li kenyelletsa ho pepesehela leseli la ultraviolet, phekolo ea mahlaseli a kotsi, ho pepeseha nako e telele ho arsenic le ts'ebetso e mpe ea tsamaiso ea 'mele ea ho itšireletsa mafung (mohlala, transplantation). Ho pepesetsoa khanya ea UV nakong ea bongoana ho kotsi haholo.
Ka mor'a ho hlahlojoa ka biopsy, hangata phekolo e etsoa ka ho tlosoa ka opereishene. Sena se ka etsoa ka ho hlajoa habonolo haeba mofetše o le monyenyane; Haeba mofetše o se o monyenyane, hangata ho buelloa opereishene ea Mohs.
Basal cell carcinoma e etsa bonyane 32% ea mefuta eohle ea kankere lefatšeng ka bophara. Ho mefuta ea kankere ea letlalo ntle le melanoma, hoo e ka bang 80% ke kankere ea basal-cell. Kua United States, mo e ka bago 35% ya banna ba bašweu le 25% ya basadi ba bašweu ba angwa ke basal cell carcinoma ka nako e itšego maphelong a bona.
○ Tlhahlobo le Kalafo
#Dermoscopy
#Skin biopsy
#Mohs surgery